Should I hold or sell CHRS stock in 2025 - Top Growth Signals From AI Tools - jammulinksnews.com
13 hours ago • Google News
Coherus BioSciences Inc (CHRS)
US$ 0.8251-19.11%
Price Chart
Key Statistics
Market Cap
$ 108.9M
P/E Ratio
2.00
Revenue (TTM)
$ 272.25M
Volume
4.38M
52W High
$ 2.43
52W Low
$ 0.66
Dividend Yield
0.00%
Beta
0.86
Technicals
50-Day MA
0.8334
200-Day MA
1.0296
52 Week High
2.43
52 Week Low
0.6603
About CHRS
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States.
Employees
221
Headquarters
Redwood City, CA
CEO
Mr. Dennis M. Lanfear
Latest News
$CHRS stock is up 8% today. Here's what we see in our data. - Quiver Quantitative
4 days ago • Google News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg